The purpose of this study was to evaluate the effect and safety of concurrent PD-1 antibody-based long-term radiotherapy followed by 2 cycles SOX with PD-1 in patients with locally advanced adenocarcinoma of esophagogastric junction.
Histologically confirmed adenocarcinoma of esophagogastric junction, and Her-2 negative.
Clinically diagnosed stage T3+orN+M0, according to CT/MRI scan.
No prior anti-tumor treatment, including surgery, chemotherapy, radiotherapy, and targeted therapy.
Eastern Cooperative Oncology Group(ECOG) performance status(PS) 0-1.
Existence of other active malignant tumors within 5 years or at the same time.
Already received chemotherapy, radiation therapy, targeted or immunotherapy.
Have any active autoimmune disease or history of autoimmune disease.
Patients with congenital or acquired immunodeficiency.